Vaxcyte (NASDAQ:PCVX) Shares Acquired Rep. Gilbert Ray Cisneros, Jr.

08 May 2025, 09:36 by Tristan Rich · The Markets Daily

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Vaxcyte, Inc. (NASDAQ:PCVX). In a filing disclosed on May 06th, the Representative disclosed that they had bought between $1,001 and $15,000 in Vaxcyte stock on April 14th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

Purchased $1,001 – $15,000 in shares of Beiersdorf Aktiengesellschaft (OTCMKTS:BDRFF) on 5/2/2025.
Purchased $1,001 – $15,000 in shares of Alkami Technology (NASDAQ:ALKT) on 4/30/2025.
Purchased $1,001 – $15,000 in shares of Merck & Co., Inc. (NYSE:MRK) on 4/29/2025.
Sold $1,001 – $15,000 in shares of DXC Technology (NYSE:DXC) on 4/29/2025.
Sold $1,001 – $15,000 in shares of DOW (NYSE:DOW) on 4/29/2025.
Sold $1,001 – $15,000 in shares of Zions Bancorporation, National Association (NASDAQ:ZION) on 4/29/2025.
Purchased $1,001 – $15,000 in shares of O’Reilly Automotive (NASDAQ:ORLY) on 4/29/2025.
Purchased $1,001 – $15,000 in shares of McKesson (NYSE:MCK) on 4/29/2025.
Sold $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 4/29/2025.
Sold $1,001 – $15,000 in shares of Humana (NYSE:HUM) on 4/29/2025.

Vaxcyte Stock Performance

Vaxcyte stock opened at $29.00 on Thursday. The stock has a 50-day simple moving average of $48.25 and a 200 day simple moving average of $75.86. The stock has a market capitalization of $3.74 billion, a P/E ratio of -6.30 and a beta of 1.27. Vaxcyte, Inc. has a 52 week low of $27.66 and a 52 week high of $121.06.

Vaxcyte (NASDAQ:PCVX – Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.02). During the same quarter last year, the company posted ($0.85) earnings per share. Research analysts forecast that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Hedge Funds Weigh In On Vaxcyte

Hedge funds have recently bought and sold shares of the company. Whipplewood Advisors LLC acquired a new stake in Vaxcyte during the 4th quarter worth about $28,000. Smartleaf Asset Management LLC grew its stake in Vaxcyte by 188.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock worth $33,000 after purchasing an additional 260 shares during the period. National Bank of Canada FI bought a new stake in Vaxcyte in the fourth quarter worth approximately $41,000. Blue Trust Inc. increased its holdings in Vaxcyte by 100.0% in the fourth quarter. Blue Trust Inc. now owns 742 shares of the company’s stock worth $61,000 after purchasing an additional 371 shares in the last quarter. Finally, Parallel Advisors LLC lifted its stake in Vaxcyte by 203.6% in the first quarter. Parallel Advisors LLC now owns 1,597 shares of the company’s stock valued at $61,000 after buying an additional 1,071 shares during the period. Institutional investors own 96.78% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Cantor Fitzgerald began coverage on shares of Vaxcyte in a report on Tuesday, April 22nd. They set an “overweight” rating for the company. Bank of America reduced their price objective on Vaxcyte from $157.00 to $137.00 and set a “buy” rating for the company in a report on Tuesday, April 1st. Guggenheim reiterated a “buy” rating and set a $160.00 target price on shares of Vaxcyte in a research note on Wednesday, March 12th. Needham & Company LLC reissued a “buy” rating and set a $90.00 price target on shares of Vaxcyte in a report on Tuesday, April 8th. Finally, The Goldman Sachs Group decreased their price objective on Vaxcyte from $138.00 to $100.00 and set a “buy” rating on the stock in a report on Tuesday, April 1st. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Vaxcyte presently has an average rating of “Buy” and a consensus target price of $136.50.

Check Out Our Latest Stock Analysis on Vaxcyte

Insiders Place Their Bets

In other news, COO Jim Wassil sold 8,000 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $73.27, for a total transaction of $586,160.00. Following the transaction, the chief operating officer now owns 154,931 shares in the company, valued at approximately $11,351,794.37. This represents a 4.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 3.10% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Vaxcyte Company Profile

(Get Free Report)

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.